Two groups of biomarkers are defined: early-changing core 1 biomarkers [amyloid positron emission tomography (PET)], cerebrospinal fluid biomarkers, and plasma biomarkers like phosphorylated tau 217, which reflect either the Aβ proteinopathy or the AD phosphorylated tau proteinopathy pathway. The gene discussed is MAPT; the disease is Alzheimer disease.